Legal Opinion
Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company
Court of Appeals for the Federal Circuit
Decided February 7, 2019No. 2017-1694PublishedCited by 11 opinions
1Opinion of the Court
Newman, Circuit Judge.
Momenta Pharmaceuticals, Inc. ("Momenta") appeals the decision of the Patent Trial and Appeal Board ("PTAB" or "Board") sustaining patentability of claims 1 through 15 (all the claims) of United States Patent No. 8,476,239 ("the '239 Patent") owned by Bristol-Myers Squibb Company ("BMS"). The appeal is dismissed for absence of standing/jurisdiction and for mootness.
BACKGROUND
The '239 Patent, entitled "Stable Protein Formulations," describes and claims specific fluid formulations of the protein *766 molecule CTLA4Ig (cytotoxic T-lymphocyte associated protein 4…
2Cases cited27 opinions
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Warth v. SeldinSupreme Court of the United States · 1975
- Spokeo, Inc. v. RobinsSupreme Court of the United States · 2016
- Friends of the Earth, Inc. v. Laidlaw Environmental Services (TOC), Inc.Supreme Court of the United States · 2000
- Clapper v. Amnesty International USASupreme Court of the United States · 2013
22 more not listed; retrieve them via the Exa API.
3Cited by11 opinions
- Avx Corporation v. Presidio Components, Inc.Court of Appeals for the Federal Circuit · 2019
- Brooklyn Brewery Corporation v. Brooklyn Brew Shop, LLCCourt of Appeals for the Federal Circuit · 2021
- Apple Inc. v. voip-pal.com, Inc.Court of Appeals for the Federal Circuit · 2020
- Can Softtech, Inc v. United StatesUnited States Court of Federal Claims · 2025
- Gateway Development Commission v. United StatesUnited States Court of Federal Claims · 2026
6 more not listed; retrieve them via the Exa API.